Our board and president

Our Board

Myeloma UK is governed by a Board of Trustees who have a wealth of experience in finance, business, and medicine. Some also have direct experience of myeloma or a related condition or have supported loved ones through their cancer.

The trustees meet with our executive team throughout the year, as both a full board and as members of various sub committees, giving their time freely to provide support, knowledge, and oversight of the vital work that Myeloma UK does.

David Ereira, Chair

David joined the Myeloma UK Board in 2024.

David Ereira OBE is a solicitor specialising in corporate restructurings and insolvency. He is a trustee of the English Touring Opera and holds non-executive board positions on a number of companies including a broadband satellite operator providing services to remote unconnected communities in the Asia Pacific region and two green energy plants.

David was previously a trustee and acting chair of Marie Curie. He was also chair of the Insolvency Service and the Public Chairs Forum.

He has four grown-up children and lives in London.

Alex Montgomery, Treasurer

Alex joined the Myeloma UK Board in 2019.

He read law at Edinburgh University and initially qualified as a solicitor with Murray Beith Murray before switching his career to focus on investment management for private clients and charities.  Alex was a Partner of Turcan Connell for several years and played a leading role in the evolution of the firm’s financial services activities into Tcam, an independent business of which he was Joint CEO until it was acquired in 2018 by Seven Investment Management.

Throughout his career Alex has been involved in advising charity clients and he currently serves as a Trustee of a grant making foundation.

Alex said “Myeloma UK is an important organisation that plays a critical role in improving the lives of patients. I very much believe that the objectives of the charity to support current myeloma patients and their families, to drive improvements to diagnosis and treatments, and to amplify the patient voice in healthcare decision making deliver a positive outcome for patients and their families”.

Paul Brocklehurst, Trustee

Paul Brocklehurst joined the Myeloma UK Board in 2021.

Paul has worked as a Chief Information Officer (CIO) for the past 20 years with a proven track record of strategic technology leadership across both public and private sector organisations.

Paul has expert knowledge of technology and transformation change, and has significant experience in the initiation and management of business change. Further specialisms also include management with responsibilities for programme delivery, governance, and risk management.

Paul said: “It is an honour to be joining the board of Myeloma UK, the organisation plays an important role in improving and supporting the lives of patients. I am excited to have this opportunity to contribute towards the future development of the organisation”.

Andrea Abrahams, Trustee

Andrea joined the Myeloma UK Board in 2021.

Andrea has worked in the pharmaceutical industry for the past 30 years in a variety of sales, training, and marketing roles at both a UK and global level. She has led and managed sales and marketing teams and been responsible for strategy development and implementation as well as linking her work into pricing and re-imbursement teams, policy, and patient advocacy teams. At a global level, she has also worked with the research and development teams to advise on how development programmes could be commercialised in order to ensure patients receive the therapies best suited to their condition.

Andrea lost her partner, Adam, to myeloma at the age of 55 after a very short period of time resulting from a late diagnosis. She is committed to delivering better outcomes for future patients and has previously served on a Myeloma UK Early Diagnosis sub-committee.

Andrea said: “It is a privilege to be joining the board of Myeloma UK, a charity that has supported me and my family in the past. The organisation’s focus on patients, research, and driving access to medicines will ensure better patient outcomes for Myeloma patients and is a vision that I personally am excited to be able to support”.

Polly Hughes, Trustee

Polly joined the Myeloma UK Board in 2022.

Polly has over 20 years experience delivering successful strategies and income generation programmes for a diverse range of U.K. and international charitable organisations.

Her fundraising experience encompasses corporate partnerships, major gifts at 6 and 7 figure level,  UK and International Events, Grants, trusts and legacies as well as statutory income programmes with a focus on helping charities deliver their short, medium and longer term objectives.

“Having seen firsthand the positive impact of early diagnosis for blood cancer within my family. It’s a privilege to be supporting Myeloma U.K as we transform the experience for myeloma patients and their loved ones.”

Deb Lancaster, Trustee

Deb joined the Board of Trustees in 2024.

Deb has worked in the pharmaceutical industry for over 30 years, 25 of them in the field of oncology. Her most recent roles in the industry have been as Market Access Director at Roche and Novartis.

Career highlights include launching Herceptin and gaining reimbursement for the first CAR-T treatment in the UK – leading very expert teams in both cases. Deb changed career three years ago and is now employed as Service Owner at Genomics England Ltd, where she enjoys working with extremely clever people internally, in academia and the biotech industry to further the research benefits of genomic medicine for NHS patients with cancer and rare disease.

She is passionate about equity of access to healthcare, particularly in the field of cancer, where so much more remains to be discovered and implemented.

Rachel Snow-Miller, Trustee

Rachel joined the Board of Trustees in 2024.

With over 25 years public sector experience Rachel has a background in housing and regeneration but most recently has over 10 years’ experience in the NHS building partnerships and relationships. Her various roles in the NHS have including working both nationally in a range of programmes and locally as a commissioner of mental health and learning disability services. Rachel is currently working in NHS England and is passionate about the improving physical and mental health for all in an inclusive and supportive NHS.

She has held various roles on boards over her career including a school for children and young people with learning disabilities and as vice chair of Crosby Housing Association.

Dr Neil Rabin, Trustee

Dr Rabin joined the Board of Trustees in 2025.

Dr Rabin is a consultant haematologist with a specialist interest in myeloma and plasma cell disorders at University College London Hospital (UCLH) and North Middlesex University Hospital (Royal Free London Group), as well as Honorary Associate Professor at University College London (UCL). He graduated from University College London Medical School and completed his postgraduate training in London. He was awarded a PhD from University College London for his work investigating novel therapies for myeloma bone disease, prior to taking up his consultant post.

In his current role he works within the large myeloma team at UCLH where he is responsible for the myeloma autologous stem cell programme. He is principal and co-investigator on several studies evaluating new treatments for myeloma, both at diagnosis and in relapse. He is actively involved in training and education and previously was Training Programme Director for Haematology (North Central London).

Dr Rabin has been on the Executive Committee of the UK Myeloma Society since 2013 and was Chair from 2021 until 2023. He has particular interest in advocacy and promoting the care of patients at a national level.

Chris Coyne, Trustee

Chris Coyne joined the Board of Trustees in 2026.

As a patient and member of Myeloma UK’s Under-50s Support Group, Chris is keen to amplify the voices of younger people affected by myeloma. A senior operational leader with many years of experience working in the London Market insurance industry, he is currently on long-term sick leave to focus on his health.

He said: “I am delighted to be joining the board of Myeloma UK, a charity that has helped support me with my own myeloma journey. I am particularly excited about the five-year strategy focused on preventing myeloma, treating myeloma and living well with myeloma.”

Luigi Sacchetti, Trustee

Luigi Sacchetti joined the Board of Trustees in 2026.

An executive with international experience across many industries, Luigi currently serves as Chief Financial Officer (Europe, Middle East and Africa) for global firm Circana. ;As a dual citizen with a personal connection to myeloma, he is keen to make sure people in the UK have access to the same cutting-edge treatments as their peers across the Channel.

He said: “Improving outcomes for people with myeloma is really important to me. Italy and other countries have access to drugs that aren’t available in the UK and that’s fundamentally wrong. Everyone should be able to access the drugs they need and that’s an area of Myeloma UK’s work I feel passionate about.”

Dr Sally Moore, Trustee

Dr Sally Moore joined the Board of Trustees in 2026.

Well known as the co-host of the popular podcast The Myeloma Minutes, Sally is a Bristol-based haematologist with a particular interest in maximising quality of life and improving outcomes in older, less fit myeloma patients.

She is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society. She is also Principal Investigator on multiple clinical trials.

She said: “Working with Myeloma UK is an honour. The charity massively punches above its weight. What it does beautifully is advocate for patients and ensure that there is as much equity as possible in terms of access to treatment. It’s highly regarded amongst the clinical community and anchors us all in what really matters for patients. It’s the glue that pulls us together in that shared agenda; I firmly believe that.”

Rebecca Sudworth, Trustee

Rebecca Sudworth joined the Board of Trustees in 2025.

Rebecca is a senior civil servant with a varied career in the public and third sectors, always looking for roles in which she can change things for the better. In her current role as Director of Policy at the Food Standards Agency, Rebecca is responsible for keeping food safe, making regulatory decisions and recommendations about which food and animal feed is allowed on the GB market, and making sure that rules about food are effective and well-enforced.

Alongside work, Rebecca has previously held a number of non-executive roles and is currently Deputy Carers Champion for the Civil Service.

She said: “I’m particularly interested in how we can use science and evidence to influence and change decisions about how myeloma is treated, and how people with myeloma and their families are supported. I’m also keen to understand how we can reach out to a wider range of people affected by myeloma.”

Christine Skeet, Trustee

Christine Skeet joined the Board of Trustees in 2025.

A clinical nurse specialist with nearly 20 years’ experience in haematology, Christine founded the Derby Myeloma Support Group and has collaborated on a range of global initiatives with the likes of Myeloma Patients Europe and Frontiers in Myeloma to tackle health inequalities and improve treatment access.

She said: “Myeloma UK is right at the heart of the community and I am thrilled to be able to contribute to their ongoing work. Having worked alongside Myeloma UK since I became a clinical nurse specialist in 2009, I have seen firsthand the difference the charity makes to patients and their families on a daily basis. I see my appointment as a trustee as a way of ensuring that the patients voice and perspective remain at the centre of Myeloma UK’s work.”